» Articles » PMID: 11750193

Survival and Cause of Death After Myocardial Infarction: the Danish MONICA Study

Overview
Publisher Elsevier
Specialty Public Health
Date 2001 Dec 26
PMID 11750193
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

As part of the Danish WHO MONICA study, a register of patients with myocardial infarction was established in 1982, covering 11 municipalities in the western part of Copenhagen County, Denmark. During the period 1982-91, all cases of myocardial infarction among citizens aged 25-74 years were registered and validated according to the criteria set up for the WHO MONICA project. Short-term (28 days) and long-term (up to 15 years) survival in three periods were compared. The rate of mortality after a non-fatal myocardial infarction was compared with that of the general population, and causes of death were analyzed. Short-term survival did not change during the study period, whereas long-term survival improved for men but did not change for women. The excess mortality rate among female patients over that of the general population was due to ischemic heart disease, other cardiovascular diseases, cancer and other diseases. The excess mortality among male patients was due only to cardiovascular diseases.

Citing Articles

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study.

Ravangard R, Ghanbari M, Attar A, Jafari A Health Sci Rep. 2024; 7(7):e2240.

PMID: 38974330 PMC: 11225077. DOI: 10.1002/hsr2.2240.


Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia.

Shah K, Willson M, Agresta B, Morton R Pharmacoecon Open. 2022; 7(1):49-62.

PMID: 36121638 PMC: 9929017. DOI: 10.1007/s41669-022-00364-0.


Cost-Effectiveness of Antihypertensive Deprescribing in Primary Care: a Markov Modelling Study Using Data From the OPTiMISE Trial.

Jowett S, Kodabuckus S, Ford G, Hobbs F, Lown M, Mant J Hypertension. 2022; 79(5):1122-1131.

PMID: 35266409 PMC: 8997697. DOI: 10.1161/HYPERTENSIONAHA.121.18726.


Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?.

Berkelmans G, Greving J, van der Graaf Y, Visseren F, Dorresteijn J Diagn Progn Res. 2020; 4:4.

PMID: 32318625 PMC: 7161238. DOI: 10.1186/s41512-020-00072-5.


Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

de Jong L, Groeneveld J, Stevanovic J, Rila H, Tieleman R, Huisman M PLoS One. 2019; 14(9):e0222658.

PMID: 31527894 PMC: 6748426. DOI: 10.1371/journal.pone.0222658.